Back to Atlases main

Breast Cancer Atlas

Visit the Gray BRCA Pre-cancer Atlas View Narrated Data View Curated Data View Automated Data

Publications

Qualification of a multiplexed tissue imaging assay and detection of novel patterns of HER2 heterogeneity in breast cancer

Qualification of a multiplexed tissue imaging assay and detection of novel patterns of HER2 heterogeneity in breast cancer

Guerriero JL, Lin JR, Pastorello RG, Du Z, Chen YA, Townsend M, Shimada K, Hughes ME ... Santagata S (2024).
npj Breast Cancer, 10(2). https://doi.org/10.1038/s41523-023-00605-3
A human breast atlas integrating single-cell proteomics and transcriptomics.

A human breast atlas integrating single-cell proteomics and transcriptomics.

Gray GK, Li CM-C, Rosenbluth JM, Selfors LM, Girnius N, Lin J-R, Schackmann RCJ, Goh WL, Moore K,...Brugge JS. (2022).
Developmental Cell, 57(22), 1400-1420. https://doi.org/10.1016/j.devcel.2022.05.003
Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer.

Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer.

Mehta AK, Cheney EM, Hartl CA, Pantelidou C, Oliwa M, Castrillon JA, Lin, J-R,... Guerriero, J. (2021).
Nature Cancer, 2(1), 66–82. https://doi.org/10.1038/s43018-020-00148-7
AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involution

AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involution

Schade A, Perurena N, Yang Y, Rodriguez CL, Krishnan A, Loi P, Mastellone GM, Pilla NF,... Cichowski K. (2024).
Clinical efficacy and molecular response correlates of the WEE1 inhibitor adavosertib combined with cisplatin in patients with metastatic triple-negative breast cancer.

Clinical efficacy and molecular response correlates of the WEE1 inhibitor adavosertib combined with cisplatin in patients with metastatic triple-negative breast cancer.

Keenan TE, Li T, Vallius T, Guerriero JL, Tayob N, Kochupurakkal B, Davis J, Pastorello R,... Tolaney SM. (2021).
Clinical Cancer Research, 2(1), 66-82. https://doi.org/10.1158/1078-0432.CCR-20-3089

Narrated Minerva Stories

Narrated stories use multi-step narrations and annotations to walk a viewer through key features of the data. Narrated stories distill the multidisciplinary knowledge encompassed by each dataset into a single product that grounds the scientific analyses in the underlying data and metadata. Click the Minerva story icon for an interactive view of the full-resolution images.

Temporal and spatial topography of cell proliferation in cancer
BRCA wild-type TNBC vs BRCA1-associated TNBC
Clinical Benefit - Cisplatin Biopsy
Clinical Benefit - Cis Wee1i Biopsy
No Clinical Benefit - Cis Wee1i Biopsy
No Clinical Benefit - Cisplatin Biopsy
Temporal and spatial topography of cell proliferation in cancer

Curated Minerva Stories

Curated stories provide access to images that have undergone a quality control step to remove failed markers, ensure appropriate channel intensity settings, and provide metadata about the underlying sample and image. Click the Minerva story icon for an interactive view of the full-resolution images.

TMA of 16 Breast Cancer Samples and Normal Tissue (BC03)
CK1 (BRCA wildtype)
CK2 (BRCA wildtype)
CK3_R (BRCA wildtype)
CK4_P (BRCA wildtype)
CK4_R (BRCA wildtype)
CK5 (BRCA wildtype)
CK6 (BRCA wildtype)
CK7 (BRCA wildtype)
CK8 (BRCA wildtype)
CK9 (BRCA wildtype)
CK10 (BRCA wildtype)
CK11 (BRCA wildtype)
CK12 (BRCA wildtype)
CK13 (BRCA wildtype)
CK14 (BRCA wildtype)
CK15 (BRCA wildtype)
CK16 (BRCA wildtype)
CK17_M (BRCA wildtype)
CK18_P (BRCA wildtype)
CK19_BCC (BRCA wildtype)
CK19_BCC2 (BRCA wildtype)
CK20 (BRCA wildtype)
CK21 (BRCA wildtype)
CK22 (BRCA wildtype)
CK23 (BRCA wildtype)
CK24 (BRCA wildtype)
CK25_R (BRCA wildtype)
CK26 (BRCA wildtype)
W2BC_3 (BRCA wildtype)
W8B_4 (BRCA wildtype)
K1 (BRCA mutant)
K2 (BRCA mutant)
K3 (BRCA mutant)
K4 (BRCA mutant)
K5 (BRCA mutant)
K6 (BRCA mutant)
K7 (BRCA mutant)
K8 (BRCA mutant)
K9 (BRCA mutant)
K10 (BRCA mutant)
K11 (BRCA mutant)
K12 (BRCA mutant)
K13 (BRCA mutant)
K14 (BRCA mutant)
K15 (BRCA mutant)
K16 (BRCA mutant)
K17 (BRCA mutant)
K18 (BRCA mutant)
K19 (BRCA mutant)
K20 (BRCA mutant)
K21 (BRCA mutant)
K22 (BRCA mutant)
K23 (BRCA mutant)
K24 (BRCA mutant)
K26 (BRCA mutant)
K27 (BRCA mutant)

Automated Minerva Stories

Automated stories provide basic image viewing with automatic rendering settings, enabling rapid, lightweight sharing of highly multiplexed images, without download. Click the Minerva story icon for an interactive view of the full-resolution images.

BRCA1-associated-9
BRCA1-associated TNBC 8
BRCA1-associated TNBC 7
BRCA1-associated TNBC 6
BRCA1-associated TNBC 5
BRCA1-associated TNBC 4
BRCA1-associated TNBC 3
BRCA1-associated TNBC 2
BRCA1-associated-10
BRCA1-associated TNBC 1
BRCA wild-type TNBC (BRCA-WT-6)
BRCA wild-type TNBC (BRCA-WT-5)
BRCA wild-type TNBC (BRCA-WT-4)
BRCA wild-type TNBC (BRCA-WT-3)
BRCA wild-type TNBC (BRCA-WT-2)
BRCA wild-type TNBC (BRCA-WT-1)

Funding

This research is funded by the Gray Foundation Basser Initiative, Ludwig Cancer Research, and the National Cancer Institute (NCI U54 CA225088).